Neoantigen vaccines for triple negative breast cancer
AssigneeWashington University
InventorsWilliam Gillanders, Ted Hansen, S. Peter Goedegebuure
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to compositions and methods of treating Triple Negative Breast Cancer (TNBC) in a human subject. A method of treating TNBC in a human subject includes administering a therapeutically effective amount of a neoantigen vaccine composition comprising a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, or a nucleic acid molecule encoding such a protein.
Claims24
A fusion protein comprising at least one triple negative breast cancer (TNBC)-associated neoantigen epitope joined to a mutant ubiquitin protein.
6-10. (canceled)
12-17. (canceled)
A nucleic acid molecule encoding a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein.
(canceled)
A method of treating Triple Negative Breast Cancer (TNBC) in an individual, the method comprising administering a therapeutically effective amount of a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein.
26-35. (canceled)
Dependencies are inferred from the claim text.